Page last updated: 2024-12-06

cephradine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cephradine is a first-generation cephalosporin antibiotic that is used to treat a variety of bacterial infections. It is synthesized by a multi-step process that starts with the fermentation of a fungus. Cephradine is effective against a wide range of gram-positive and some gram-negative bacteria. It works by inhibiting the synthesis of peptidoglycan, a key component of bacterial cell walls. Cephradine is administered orally, intravenously, or intramuscularly. It is well-absorbed from the gastrointestinal tract and is widely distributed throughout the body. The drug is commonly used to treat infections of the respiratory tract, skin, urinary tract, and middle ear. It is also used to prevent bacterial infections in patients undergoing surgery. Cephradine is studied to understand its mechanisms of action, its effectiveness against different bacteria, and its safety profile. It is also being studied for its potential use in combination therapy with other antibiotics.'

Cephradine: A semi-synthetic cephalosporin antibiotic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID38103
CHEMBL ID1604
CHEBI ID3547
SCHEMBL ID3244
MeSH IDM0003834

Synonyms (107)

Synonym
AC-1409
KBIO1_000739
DIVK1C_000739
(6r,7r)-7-{[(2r)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefradinum
7beta-[(2r)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid
cefradina
CHEBI:3547 ,
C06897
cephradine
cefradine
38821-53-3
DB01333
cephradin
(6r,7r)-7-((r)-2-amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
7-(d-2-amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid
cephradine (usp)
D00264
velosef (tn)
CED ,
anspor (tn)
cefradine (jan/inn)
IDI1_000739
hsdb 3216
velosef
cefradinum [inn-latin]
einecs 254-137-8
sq 11436
7-(d-2-amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid
velosef '125'
cefradina [inn-spanish]
velosef '500'
sefril
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6r-(6alpha,7beta(r*)))-
velosef '250'
cephradine [usan:ban]
anspor
sq-11436
eskacef
skf d 39304
brn 6075388
NINDS_000739
(6r,7r)-7-[[(2r)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
HMS502E21
cephradine anhydrous
sk&f d-39304
CHEMBL1604
nsc-756672
sk-d-39304
cefradine hydrate
sq 22022 [dihydrate]
sq-22022
(7r)-7-[[(2r)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
NCGC00183036-01
velocef
cas-38821-53-3
dtxcid002785
tox21_113488
dtxsid4022785 ,
BCP9000506
S4671
AKOS015961130
bdbm50370585
cefradine [inn]
megace f
unii-9ya6sx5s4d
megacef
cekodin
nsc 756672
9ya6sx5s4d ,
BCPP000291
NCGC00183036-02
EPITOPE ID:116210
gtpl4830
infexin
(6r,7r)-7-[(2r)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cephradine [mi]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6r-(6.alpha.,7.beta.(r*)))-
cefradine [jan]
(6r,7r)-7-(((2r)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl)amino)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
cephradine [hsdb]
cefradine [who-dd]
cefradine [ep monograph]
cefradine [mart.]
RDLPVSKMFDYCOR-UEKVPHQBSA-N
CCG-208520
SCHEMBL3244
NCGC00263658-01
tox21_113488_1
CS-4608
HY-B1156
C2988
mfcd00865048
cefradine, european pharmacopoeia (ep) reference standard
(6r,7r)-7-((r)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid
cefradine for peak identification, european pharmacopoeia (ep) reference standard
(6r,7r)-7-((r)-2-amino-2-(cyclohexa-1,4-dienyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7r)-7-((r)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
AS-75158
cephradine,(s)
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2r)-2-amino-2-(1,4-cyclohexadien-1-yl)acetyl]amino]-3-methyl-8-oxo-,(6r,7r)-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2r)-amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methyl-8-oxo-,(6r,7r)-
AMY500
C74975
Q2734674
EN300-6479201
Z2235811518

Research Excerpts

Overview

Cephradine is a useful cephalosporin for treatment of nonenterococcal gram-positive endocarditis in young heroin addicts. It is a good replacement in patients with allergy to penicillins.

ExcerptReferenceRelevance
"Cephradine was proved to be an effective antimicrobial agent for chemoprophylaxis, due to its wide antimicrobial spectrum, beta-lactamase resistance, low percentage protein binding, large volume of distribution and non metabolic degradation."( Evaluation of cephradine-chemoprophylaxis in Cesarean section.
Kotoulas, IG; Papaloucas, A; Paradelis, AG,
)
1.21
"Cephradine is a useful cephalosporin for treatment of nonenterococcal gram-positive endocarditis in young heroin addicts."( Cephradine in the treatment of infective endocarditis.
Chatterjee, S; Fiala, M; Huang, J; Kaushik, V; Lluncor, E,
)
2.3
"Cephradine is a good replacement in patients with allergy to penicillins."( Clinical and laboratory evaluation of the effect of cephradine on patients with ear, nose and throat infections.
Malmborg, AS; Meder, B; Wersäll, J, 1975
)
1.23

Treatment

ExcerptReferenceRelevance
"Oral treatment with cephradine on the other hand had no obvious influence on the endogenous flora of the mice, nor was the colonization resistance decreased."( The effect of three frequently applied antibiotics on the colonization resistance of the digestive tract of mice.
Thijm, HA; van der Waaij, D, 1979
)
0.57

Toxicity

ExcerptReferenceRelevance
" Overall clinical and bacteriologic responses were nearly identical in the two groups, and both antibiotics proved to equally safe and effective for use paediatric practice."( Comparative efficacy and safety of cephradine and cephalexin in children.
Mouallem, R, 1976
)
0.53
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"Two common freshwater algae Microcystis aeruginosa and Scenedesmus obliquus were employed as test organism to evaluate the toxic effects of the widely used antibiotic, cefradine."( Access the toxic effect of the antibiotic cefradine and its UV light degradation products on two freshwater algae.
Chen, JQ; Guo, RX, 2012
)
0.38

Pharmacokinetics

Cefadroxil is an oral cephalosporin which is similar to cephalexin and cephradine in structure and spectrum of antibacterial activity, but has different pharmacokinetic properties.

ExcerptReferenceRelevance
"A review is given on the pharmacokinetic characteristics of some cephalosporin antibiotics."( On the pharmacokinetics of cephalosporin antibiotics.
Andersson, KE, 1978
)
0.26
"Cefadroxil (Duricef, Mead Johnson and Company), resembles cephalexin and cephradine in spectrum of antibacterial activity but differs in human pharmacokinetic properties."( Bactericidal activity of cefadroxil, cephalexin, and cephradine in an in vitro pharmacokinetic model.
Buck, RE; Goodhines, RA; Leitner, F; Price, KE, 1979
)
0.74
" The effects of protein binding of some of the commonly used cephalosporins on antibacterial activity and several pharmacokinetic parameters are discussed in this communication."( Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations.
Heald, AF; Schreiber, EC; Singhvi, SM, 1978
)
0.26
" Estimations of levels were made from the pharmacokinetic data (half life, distribution volume) which serve as a basis for the recommendation of isoconcentration dosages."( [Pharmacokinetics of intravenous Cefradin in normal and restricted renal function (author's transl)].
Höffler, D; Koeppe, P, 1975
)
0.25
"In a cross-over study in 12 normal individuals, the pharmacokinetic parameters of cefalotin, cefradine and cefazolin were determined after intravenous injection of 1,000 mg of each substance."( Comparative pharmacokinetics and clinical experience with a new cephalosporin-derivative: cefazolin.
Gebert, S; Hendrischk, A; Lode, H, 1975
)
0.25
" The trauma patients exhibited significantly lower Cmax and reduced AUC."( Peroral absorption of cefroxadine in patients within the first day after severe trauma: comparison to cefroxadine pharmacokinetics in fasted, healthy volunteers.
Aiache, JM; Beyssac, E; Haberer, JP; Ritschel, WA, 1991
)
0.28
"59 ml/min/kg) and the elimination half-life was significantly longer (1."( Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects.
Gill, E; Norden, CW; Schwinghammer, TL, 1990
)
0.6
" Although the pharmacokinetic characteristics of the drugs after intravenous injection were similar to other beta-lactam antibiotics, significant differences between the cephalosporins examined were found in respect of certain kinetic parameters."( Clinical pharmacokinetics of five oral cephalosporins in calves.
Kurtz, B; Paz, R; Soback, S; Ziv, G, 1987
)
0.27
"Cefadroxil is an oral cephalosporin which is similar to cephalexin and cephradine in structure and spectrum of antibacterial activity, but has different pharmacokinetic properties."( Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine.
Santella, PJ; Tanrisever, B, 1986
)
0.71
" For both drugs most pharmacokinetic parameters were altered in pregnancy."( Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.
Ehrnebo, M; Philipson, A; Stiernstedt, G, 1987
)
0.54
"The pharmacokinetic interaction of the monobactam antibiotic aztreonam with cephradine, clindamycin, gentamicin, metronidazole, and nafcillin was investigated in five separate studies in 48 healthy male volunteers."( Pharmacokinetic interaction of aztreonam with other antibiotics.
Adamovics, J; Creasey, WA; Dhruv, R; Platt, TB; Sugerman, AA, 1984
)
0.5
" The serum concentrations, serum elimination half-life and total body clearance were significantly influenced by reduced renal function."( Relationship between pharmacokinetics and bioavailability of cefroxadine (CGP 9000) and renal function.
Bergan, T; Brodwall, EK; Larsen, EW, 1983
)
0.27
"A pharmacokinetic model has been developed, by means of which all possible time courses of the concentrations of antibiotics in the plasma of treated individuals can be exactly simulated in vitro without diluting the test organism and affecting the growth curves."( Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model.
Maurer, M; Schneider, P; Tosch, W; Zak, O, 1982
)
0.51
" The pharmacokinetic parameters of cefroxadine were obtained by analysing the serum level data of the drug based on a one-compartment open model."( Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function.
Awazu, S; Kuroda, K; Ohkawa, M; Shimamura, M; Takamae, K, 1981
)
0.26
"The pharmacokinetic parameters of cefroxadin and cephalexin were compared after simultaneous oral administration of the two cephalosporins to 21 subjects."( Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans.
Hirtz, JL; Humbert, G; Lecaillon, JB; Schoeller, JP; Vischer, W, 1980
)
0.26
" This assay was successfully applied to determine the pharmacokinetic parameters of cefroxadine in Korean healthy volunteers after an oral administration of two 250 mg cefroxadine capsules."( A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.
Choi, HM; Kang, YS; Kim, NH; Kim, W; Lee, HJ; Lee, SY; Park, JS, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" A Single group pharmacokinetic study was conducted having six healthy male volunteers of 20-24 years of age."( Pharmacokinetic study of cephradine in Pakistani healthy male volunteers.
Hashmi, K; Naqvi, BS; Shaikh, D; Shoaib, MH; Yousuf, RI, 2008
)
0.65

Bioavailability

Cephradine has been reacted with cobalt, copper, zinc and cadmium metal halides in L:M ratio of 2:1 in methanol. The products recrystallized from suitable solvents to pure crystals of consistent melting points.

ExcerptReferenceRelevance
" Smaller areas under the curve and absorption rate constants were observed for females after injection into each muscle group."( Sex differences in the intramuscular absorption and bioavailability of cephradine.
Brannick, LJ; Neiss, ES; Sugerman, AA; Vukovich, RA, 1975
)
0.49
" No difference was observed in the overall bioavailability of the three antibiotics based on comparable FD/V values."( The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.
Dean, S; Kendall, MJ; Selen, A; Welling, PG; Wise, R, 1979
)
0.5
" These parameters were subsequently used to determine the absorption rates and bioavailability of cephradine administered intramuscularly and orally."( Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans.
Bernardo, PD; Rattie, ES; Ravin, JJ, 1976
)
0.75
"The partial area method was investigated for evaluation of equivalency in the rate of absorption of immediate release formulations."( An alternative approach for assessment of rate of absorption in bioequivalence studies.
Chen, ML, 1992
)
0.28
"Gastrointestinal absorption of cefazolin, which is poorly absorbed in adults, and of cephradine, which is well absorbed in adults, was studied in rats during their development."( Effect of gastrointestinal maturation on absorption of beta-lactam antibiotics.
Mizuno, N; Morita, E; Nishikata, M; Takahashi, K, 1992
)
0.51
" Even though rate and extent of bioavailability cannot be determined from these two different population groups since the total clearance must be assumed to be different in patients and healthy subjects, a reduced bioavailability is assumed based on pathophysiologic reflections."( Peroral absorption of cefroxadine in patients within the first day after severe trauma: comparison to cefroxadine pharmacokinetics in fasted, healthy volunteers.
Aiache, JM; Beyssac, E; Haberer, JP; Ritschel, WA, 1991
)
0.28
" The relative oral bioavailability was approximately 94% in both groups."( Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects.
Gill, E; Norden, CW; Schwinghammer, TL, 1990
)
0.6
" Compound 2 is well absorbed from rat jejunum, whereas lisinopril absorption is relatively low."( Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852.
Amidon, GL; Friedman, DI, 1989
)
0.28
" The bioavailability of the drugs was about 35 per cent of the administered dose."( Clinical pharmacokinetics of five oral cephalosporins in calves.
Kurtz, B; Paz, R; Soback, S; Ziv, G, 1987
)
0.27
"Moment analysis was utilized in the evaluation of equivalency between test and reference formulations with respect to the rate of absorption for four drugs having different pharmacokinetic characteristics."( Application of moment analysis in assessing rates of absorption for bioequivalency studies.
Chen, ML; Jackson, AJ, 1987
)
0.27
" The bioavailability of oral cephradine did not differ significantly during compared with after pregnancy."( Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.
Ehrnebo, M; Philipson, A; Stiernstedt, G, 1987
)
0.84
" Both drugs were equally well absorbed from all of the tested formulations; identical percentages of the dose were recovered in the urine in all cases."( Pharmacokinetic comparison of cefroxadin (CGP 9000) and cephalexin by simultaneous administration to humans.
Hirtz, JL; Humbert, G; Lecaillon, JB; Schoeller, JP; Vischer, W, 1980
)
0.26
" Bioavailability of cephradine was determined in normal goats after a single intramuscular dose."( Disposition kinetics of cephradine in normal and Escherichia coli infected goats.
Atef, M; el-Komy, AA; el-Sayed, MG, 1994
)
0.92
" Valacyclovir, a water soluble amino acid ester prodrug of acyclovir has been reported to increase the oral bioavailability of acyclovir but its absorption mechanism is unknown."( 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
Amidon, GL; Covitz, KM; de Vrueh, RL; Han, H; Lee, CP; Oh, DM; Rhie, JK; Sadée, W; Smith, PL, 1998
)
0.3
" The advantage of the model is to separately define the extent and rate of absorption for the dosage and EHC after oral administration."( A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.
Moriwaki, T; Yamamoto, A; Yasui, H, 2003
)
0.32
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
" Since the presence of complexing ligand may affect the bioavailability of a metal in the blood or tissues, therefore, in order to study the probable interaction of cephradine with essential and trace elements present in human body, cephradine has been reacted with cobalt, copper, zinc and cadmium metal halides in L:M ratio of 2:1 in methanol and the products recrystallized from suitable solvents to pure crystals of consistent melting points."( Synthesis and antibacterial activity of cephradine metal complexes : part II complexes with cobalt, copper, zinc and cadmium.
Afzal, M; Arayne, MS; Sultana, N, 2005
)
0.79
" Since the presence of complexing ligand may affect the bioavailability of a drug in blood or tissues, therefore, in order to study the probable interaction of cephradine with antacids all the reaction conditions were simulated to natural environments."( Cephradine antacids interaction studies.
Afzal, M; Arayne, MS; Sultana, N, 2007
)
1.98
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Cephradine given as a 1 g bolus intravenously with anaesthetic induction provides satisfactory concentrations for antibacterial prophylaxis during gall bladder surgery but a regimen of oral and intramuscular dosage was found to be unsatisfactory. Total urinary recovery of antibiotic activity accounted for almost 90 percent of dosed cephradines and cephalexin compared to 55 percent of cefaclor.

ExcerptRelevanceReference
" The results obtained confirm that, for cephalosporins, the dosage schedule should be adjusted taking into account the potency of the drug (MIC) and its rate of elimination."( [Correlation between antibacterial activity of some cephalosporins and pharmacokinetic properties "in vitro" (author's transl)].
de Carneri, I; Grasso, S; Meinardi, G; Tamassia, V, 1979
)
0.26
"A polarographic method has been developed for the quantitative analysis of cephradine and its dosage forms."( DC polarography of cephradine and its application to capsules.
Gonzalez, EM; Nuñez-Vergara, LJ; Squella, JA, 1979
)
0.82
" Total urinary recovery of antibiotic activity accounted for almost 90 percent of dosed cephradine and cephalexin compared to 55 percent of dosed cefaclor."( The pharmacokinetics of the oral cephalosporins cefaclor, cephradine and cephalexin.
Dean, S; Kendall, MJ; Selen, A; Welling, PG; Wise, R, 1979
)
0.73
" Recommendations for dosage schedules for subjects with renal failure have been made."( The administration of cephradine to patients in renal failure.
Briggs, JD; Solomon, AE, 1975
)
0.57
" With the chosen dosage the concentrations of the antibiotic in the pericardial exudate are higher than the MIC values of most pathogen bacteria."( [Cephradine in open heart serugery. Concentrations of cephradine in pericardial exudate and serum after cardiac surgery (author's transl)].
Adam, D; Krebber, HJ; Raff, W; Voigt, I, 1977
)
1.17
" The results indicate that cephradine obeys dose-independent kinetics and that biological availability is complete from all dosage forms."( Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans.
Bernardo, PD; Rattie, ES; Ravin, JJ, 1976
)
0.83
" dosage form."( H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes.
Hori, R; Inui, K; Katsura, T; Okano, T; Takano, M; Tomita, Y, 1992
)
0.28
" Provisional oral dosage regimens were computed for each cephalosporin on the basis of the MIC data and the kinetic parameters derived from intravenous and oral drug administration."( Clinical pharmacokinetics of five oral cephalosporins in calves.
Kurtz, B; Paz, R; Soback, S; Ziv, G, 1987
)
0.27
" Tonsillar tissues were taken 2 h after dosing and blood samples before, 1, 2, 4 and 6 h after the drug administration in 8 out of 20 enrolled patients."( Correlation between plasma and tonsillar levels of cefroxadine.
Bichisao, E; Borghi, C; Fraschini, F; Montanari, M; Scaglione, F; Vago, F, 1988
)
0.27
" The dosage yielded too high plasma trimethoprim concentrations, while sulfamethoxazole dialysate concentrations were too low."( Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.
Berden, JH; Hekster, YA; Martea, M; Voets, AJ; Vree, TB, 1987
)
0.27
" Antibiotic concentrations in cornea and aqueous humor were measured for 4 hrs following dosing using bioassay and radioimmunoassay."( Effect of inflammation on antibiotic penetration into the anterior segment of the rat eye.
Badenoch, PR; Coster, DJ; McDonald, PJ, 1986
)
0.27
" It is concluded that the dosage of both cefazolin and cephradine should be increased when treating infections in pregnant women in order to obtain the same antibacterial effect as when treating non-pregnant women."( Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women.
Ehrnebo, M; Philipson, A; Stiernstedt, G, 1987
)
0.79
"In this double-blind, randomized, multicenter trial, an oral dosing regimen of 500 mg twice daily (BID) of cephradine was evaluated for the treatment of acute uncomplicated urinary tract infections due to susceptible pathogens."( A lower dose regimen for cephradine capsules in the treatment of urinary tract infections.
Brosof, AB; Spitzer, TQ, 1980
)
0.78
" Cefroxadine dry syrup was in principle administered at the dosage of 10 mg per kilogram of body weight 3 times a day."( [Use of cefroxadine dry syrup in the management of acute skin infections in children (author's transl)].
Arakawa, K; Arata, J; Fujimoto, W; Hagiyama, M; Hiramatsu, H; Kashiwa, N; Masuda, T; Miyoshi, K; Nakagawa, S; Nakakita, T; Nishihara, O; Nishimoto, M; Nohara, N; Okuma, N; Suwaki, M; Tada, J; Take, M; Tanaka, A; Tokumaru, S; Ueki, H; Umemura, S; Yamada, M; Yamamoto, Y, 1981
)
0.26
" Therefore, cephradine given as a 1 g bolus intravenously with anaesthetic induction provides satisfactory concentrations for antibacterial prophylaxis during gall bladder surgery but a regimen of oral and intramuscular dosage was found to be unsatisfactory."( Peroperative cephradine concentrations in the gall bladder wall and bile.
Bullen, BR; Kester, RC; Ramsden, CH, 1982
)
1.01
" On the other hand, the necessity of the optimum dose regimen for not only antibiotics but also other drugs has been emphasized to achieve the maximum pharmacological effects with minimal dosage or to prevent the side-effects and sequelae."( [High-performance liquid chromatographic micro-assay for cefradine in biological fluids (author's transl)].
Hayashi, Y, 1981
)
0.26
" Clinical responses: CXD was administered, for 7 days, to 33 children with scarlet fever in the dosage of greater than or equal 20 approximately less than 60 mg/kg/day (7 children in greater than or equal to 20 approximately 30 mg/kg/day, 21 in greater than or equal to 30 approximately less than 40 mg/kg/day and 5 in greater than or equal to 40 approximately less than 60 mg/kg/day)."( [Clinical evaluation of cefroxadine dry syrup in pediatric field (author's transl)].
Hachimori, K; Minamikawa, I; Minamitani, M; Suzuki, M, 1981
)
0.26
" The method was employed for the quantitative analysis of reference substances, bulk samples and pharmaceutical dosage forms."( Quantitative analysis of cefradine by liquid chromatography on poly(styrene-divinylbenzene).
Hendrix, C; Hoogmartens, J; Pijcke, M; Roets, E; Yun, LM, 1993
)
0.29
" The advantage of the model is to separately define the extent and rate of absorption for the dosage and EHC after oral administration."( A recirculatory model with enterohepatic circulation by measuring portal and systemic blood concentration difference.
Moriwaki, T; Yamamoto, A; Yasui, H, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
beta-lactam antibiotic allergenAny beta-lactam antibiotic which causes the onset of an allergic reaction.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency5.95690.000811.382244.6684AID686979
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency9.52050.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)IC50 (µMol)15,150.00000.18000.19000.2000AID679008; AID681608
Solute carrier family 15 member 1Homo sapiens (human)Ki4,904.90000.18003.39339.8000AID238858; AID681115
Solute carrier family 22 member 6Homo sapiens (human)IC50 (µMol)1,600.00000.27004.53069.9000AID681331
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki56.00003.00006.47788.5000AID681114; AID681347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (132)

Assay IDTitleYearJournalArticle
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID543955Antibacterial activity against chloramphenicol, tetracycline-resistant Staphylococcus aureus COL-S carrying SAmecA/mecI-mecR1 plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID681331TP_TRANSPORTER: inhibition of 6-Carboxyfluorescein uptake in OAT1-expressing CHO cells2000Analytical biochemistry, Jul-15, Volume: 283, Issue:1
Fluorescence-based assay for the interaction of small molecules with the human renal organic anion transporter 1.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID613260Antifungal activity against Candida albicans ATCC 10231 after 24 hrs by NCCLS M38-P broth dilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID575417Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID1219874Inhibition of recombinant human ABCC3 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID1435414Anti-bacterial activity against Staphylococcus aureus ATCC 10832 measured after 24 hrs by microtiter broth dilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1435416Anti-bacterial activity against Bacillus subtilis ATCC 33712 measured after 24 hrs by microtiter broth dilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID575340Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID682279TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.02 uM, Cephradine: 2500 uM) in OCTN2-expressing HeLa cells2000The Journal of biological chemistry, Jan-21, Volume: 275, Issue:3
beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID679008TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells1998Pharmaceutical research, Aug, Volume: 15, Issue:8
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1435413Anti-bacterial activity against Escherichia coli ATCC 11303 measured after 24 hrs by microtiter broth dilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID1435415Anti-bacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 measured after 24 hrs by microtiter broth dilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID613257Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by NCCLS M7-A6 broth dilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID681347TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID667376Antibacterial activity against Escherichia coli ATCC 11303 after 24 hrs by microtiter broth dilution method2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID543952Antibacterial activity against tetracycline-resistant Staphylococcus aureus COL-S carrying SAmecA plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID613258Antibacterial activity against Bacillus subtilis ATCC 33712 after 24 hrs by NCCLS M7-A6 broth dilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID667373Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by microtiter broth dilution method2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID613255Antibacterial activity against Escherichia coli ATCC 11303 after 24 hrs by NCCLS M7-A6 broth dilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID667375Antibacterial activity against Bacillus subtilis ATCC 33712 after 24 hrs by microtiter broth dilution method2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID679005TP_TRANSPORTER: uptake in PEPT1-expressing CHO cells1999Journal of pharmaceutical sciences, Mar, Volume: 88, Issue:3
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1219875Inhibition of recombinant human ABCC4 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1435411Anti-fungal activity against Candida albicans ATCC 10231 measured after 24 hrs by microtiter broth dilution method2017European journal of medicinal chemistry, Jan-27, Volume: 126Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID667372Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by microtiter broth dilution method2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID543951Antibacterial activity against oxacillin, chloramphenicol, erythromycin-susceptible and tetracycline-resistant Staphylococcus aureus COL-S with SCCmec excised2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID543954Antibacterial activity against chloramphenicol-resistant Staphylococcus aureus COL carrying mecI-mecR1 plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID613256Antibacterial activity against Staphylococcus aureus ATCC 10832 after 24 hrs by NCCLS M7-A6 broth dilution method2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
AID543950Antibacterial activity against oxacillin, chloramphenicol-susceptible and erythromycin, tetracycline-resistant Staphylococcus aureus COL2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID679327TP_TRANSPORTER: uptake in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID543956Antibacterial activity against chloramphenicol, tetracycline-resistant Staphylococcus aureus COL-S carrying SSpbpD/mecI-mecR1 plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681350TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID681608TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells1999Journal of pharmaceutical sciences, Mar, Volume: 88, Issue:3
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID679951TP_TRANSPORTER: uptake in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID679878TP_TRANSPORTER: inhibition of Ceftibuten uptake (Ceftibuten: 1000 uM, Cephradine: 10000 uM) in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID543953Antibacterial activity against tetracycline-resistant Staphylococcus aureus COL-S carrying SSpbpD plasmid2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Reconstruction of the phenotypes of methicillin-resistant Staphylococcus aureus by replacement of the staphylococcal cassette chromosome mec with a plasmid-borne copy of Staphylococcus sciuri pbpD gene.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1219873Inhibition of recombinant human ABCC2 expressed in insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID667374Antibacterial activity against Pseudomonas aeruginosa ATCC 49189 after 24 hrs by microtiter broth dilution method2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and antimicrobial evaluation of 3-methanone-6-substituted-benzofuran derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (566)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990370 (65.37)18.7374
1990's79 (13.96)18.2507
2000's49 (8.66)29.6817
2010's53 (9.36)24.3611
2020's15 (2.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.71 (24.57)
Research Supply Index6.55 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index118.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials101 (16.97%)5.53%
Reviews21 (3.53%)6.00%
Case Studies42 (7.06%)4.05%
Observational0 (0.00%)0.25%
Other431 (72.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Operational Research on Management at First Level Facilities for Children With Severe Pneumonia [NCT01312792]300 participants (Actual)Interventional2010-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]